Mortality file
The 38% Case-Fatality Rate: Why Hantavirus Remains One of the Deadliest Respiratory Viruses
Few infectious diseases in the modern era kill nearly four in ten patients who reach hospital care. The hantavirus number isn't a statistical artefact - but it is a number that can move.
The number you'll read everywhere is 38%. Sometimes 36%, sometimes ‘approximately 35–40%’. It refers to the case-fatality rate of hantavirus pulmonary syndrome - the proportion of patients with severe respiratory symptoms who die. It is high. It is also, on closer inspection, more nuanced than the headline.
Where the 38% comes from
The figure is derived primarily from CDC surveillance of US cases since 1993, the year Sin Nombre virus was identified after the Four Corners outbreak. Across more than 800 confirmed cases, around 38% have died.
Three things are worth knowing about that figure:
- It refers specifically to symptomatic, hospitalised HPS - not to asymptomatic infection (which exists but is rare for HPS, unlike for the milder Old World hantaviruses).
- It has not changed meaningfully in three decades of US surveillance, despite improved intensive care.
- Different hantaviruses have different CFRs. Sin Nombre sits around 38%. Andes virus sits in the 25–40% range. The Old World species that cause hantavirus haemorrhagic fever with renal syndrome (HFRS) - Hantaan, Seoul, Puumala - are far less lethal, with CFRs from 0.1% to perhaps 12%.
Why is it so high?
Three factors compound:
- Late presentation. The flu-like prodrome buys the virus four to five days before anyone seeks care.
- Delayed diagnosis. Most ED physicians have never seen HPS; the diagnosis is rarely first on the list.
- Catastrophic physiology. The cardiopulmonary phase can deteriorate from ‘short of breath’ to ‘failed resuscitation’ in hours.
Why hasn't it dropped?
Honestly, because we haven't found an intervention that works upstream. There is no licensed antiviral specific to hantavirus; ribavirin showed early promise for HFRS but disappointing results for HPS. There is no licensed hantavirus vaccine outside South Korea (Hantavax, for Hantaan virus). Monoclonal-antibody candidates are in preclinical and early clinical stages but not yet deployable.
Downstream, intensive care has improved. ECMO - extracorporeal membrane oxygenation, essentially an artificial lung - has been a meaningful addition. The Chilean experience, where ECMO is now standard for severe HCPS, suggests case-fatality rates can drop into the high 20s with aggressive use. But ECMO requires a tertiary centre and a transport system; not every patient gets one.
Comparing to other respiratory threats
| Disease | Typical CFR (severe cases) | Comparison context |
|---|---|---|
| Hantavirus pulmonary syndrome | ~38% | Sin Nombre, North America |
| MERS-CoV | ~34% | Middle East, person-to-person but limited |
| Ebola virus disease | ~50% average | Highly variable by outbreak |
| H5N1 avian influenza (human) | ~50% | Very rare human cases |
| SARS (2003) | ~10% | Limited dataset |
| COVID-19 (severe / hospitalised) | ~10–20% pre-vaccine | Dramatic drop post-vaccine |
| Seasonal influenza | <0.1% | Population denominator |
The future of the number
Several things could move the 38% in the next decade: licensed monoclonal antibody therapy (most promising near-term), broader ECMO availability, faster diagnostic tests usable in primary care, and routine consideration in differential diagnosis for unexplained acute respiratory illness with rodent exposure. None of those are a vaccine, but together they could matter.
Editorial note
This article is intended as public information, not individual medical advice. If you are concerned about your symptoms, contact a qualified healthcare professional. We update outbreak reporting as new primary-source information becomes available.